Skip to main content
Fig. 10 | BMC Urology

Fig. 10

From: Identification and experimental validation of a sialylation–related long noncoding RNA signature for prognosis of bladder cancer

Fig. 10

Tumour mutational burden (TMB) and Drug susceptibility analysis. (A) The waterfall chart of the frequently mutated genes in the high-risk group. (B) The waterfall chart of the frequently mutated genes in the low-risk group. (C) Kaplan–Meier curves of high- and low-TMB on OS. (D) Kaplan–Meier curves of TMB and risk score on OS. exploration of the risk signature and drug sensitivity. (E) Docetaxel. (F) Sorafenib. (G) Dasatinib. (H) Cisplatin

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us